JULY 9, 2024
Use of Dalbavancin in Optimizing the Management of ABSSSIs in Patients With Obesity or Diabetes
This Special Report reviews data on the use of dalbavancin for the treatment of ABSSSIs to support safety and efficacy in high-risk populations, including obese and diabetic patients.
Download to read this article in PDF format:
Use of Dalbavancin in Optimizing the Management of ABSSSIs in Patients With Obesity or Diabetes
This article is in PDF format and it requires Adobe Reader.
If you do not have Adobe Reader installed on your computer then please download and install from the link below.
Download Adobe Reader